Literature DB >> 7503009

Role of beta-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy.

M White1, F Yanowitz, E M Gilbert, P Larrabee, J B O'Connell, J L Anderson, D Renlund, P Mealey, W T Abraham, M R Bristow.   

Abstract

The effect of beta-adrenergic receptor downregulation on peak exercise response in patients with heart failure has not been directly investigated. Seventy-two patients with idiopathic dilated cardiomyopathy who had a mean ejection fraction of 23 +/- 1% (mean +/- SEM) and New York Heart Association class II or III symptoms were investigated. Subjects underwent maximal exercise testing on a bicycle or a treadmill, hemodynamic assessment by right heart catheterization, and measurement of total beta-adrenergic receptor density by 125I-iodocyanopindolol binding performed in the right ventricular endomyocardial biopsy tissue and in peripheral lymphocytes. Endomyocardial biopsy beta-adrenergic receptor density (Bmax) was markedly decreased (45 +/- 2 fmol/mg), and significantly lower than lymphocytes Bmax (107 +/- 14 fmol/mg; p < 0.05). By univariate analysis, all exercise variables correlated significantly with biopsy tissue Bmax but not with lymphocyte Bmax. Maximal exercise oxygen consumption (VO2max) yielded the highest correlation with Bmax (r2 = 0.61, p < 0.001). By stepwise regression analysis, VO2 max, delta heart rate x systolic blood pressure, and ejection fraction were all independently related to Bmax. Myocardial beta-adrenergic receptor downregulation is likely to be partially responsible for the reduced chronotropic and inotropic responses to peak exercise in patients with mild to moderate symptomatic heart failure due to idiopathic dilated cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7503009     DOI: 10.1016/s0002-9149(99)80355-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  Cardiac receptor physiology and its application to clinical imaging: present and future.

Authors:  H Tseng; J M Link; J R Stratton; J H Caldwell
Journal:  J Nucl Cardiol       Date:  2001 May-Jun       Impact factor: 5.952

2.  Chronic heart failure, chronotropic incompetence, and the effects of beta blockade.

Authors:  K K A Witte; J G F Cleland; A L Clark
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

3.  Exercise capacity in pediatric heart transplant candidates: is there any role for the 14 ml/kg/min guideline?

Authors:  B B Das; A L Taylor; M M Boucek; R W Wolfe; A T Yetman
Journal:  Pediatr Cardiol       Date:  2006 Mar-Apr       Impact factor: 1.655

Review 4.  Exercise testing with concurrent beta-blocker usage: is it useful? What do we learn?

Authors:  Eugene E Wolfel
Journal:  Curr Heart Fail Rep       Date:  2006-06

Review 5.  Age-associated alterations in calcium current and its modulation in cardiac myocytes.

Authors:  Y Y Zhou; E G Lakatta; R P Xiao
Journal:  Drugs Aging       Date:  1998-08       Impact factor: 3.923

Review 6.  Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents.

Authors:  S F Shakar; M R Bristow
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

7.  Inhibition of N-type calcium channels in cardiac sympathetic neurons attenuates ventricular arrhythmogenesis in heart failure.

Authors:  Dongze Zhang; Huiyin Tu; Chaojun Wang; Liang Cao; Wenfeng Hu; Bryan T Hackfort; Robert L Muelleman; Michael C Wadman; Yu-Long Li
Journal:  Cardiovasc Res       Date:  2021-01-01       Impact factor: 10.787

Review 8.  Biologic rationale for the use of beta-blockers in the treatment of heart failure.

Authors:  Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2004-04       Impact factor: 4.214

Review 9.  The effects of neurohormonal antagonism on pathologic left ventricular remodeling in heart failure.

Authors:  W L Lombardi; E M Gilbert
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 3.955

Review 10.  Deactivation of the sympathetic nervous system in patients with chronic congestive heart failure.

Authors:  E M Gilbert; J D Port
Journal:  Curr Cardiol Rep       Date:  2000-05       Impact factor: 3.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.